Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial

Transfusion Science

Volumn 17, Issue 4, 1996, Pages 643-649

  Moviglia, Gustavo Antonio ^a  

^a Regina Mater Foundation   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR VACCINE;

ADVANCED CANCER; ANTIGEN RECOGNITION; B LYMPHOCYTE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CELL FUSION; CELL KILLING; CELL SUSPENSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; FEMALE; HOST; HUMAN; HYBRIDOMA; IMMUNE SYSTEM; IMMUNIZATION; INFLUENZA; LYMPHOCYTE; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TUMOR CELL; VACCINATION;

EID: 0347874849     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(96)90103-4     Document Type: Conference Paper

References (20)

1. Hellström I, Hellström KE: Tumor immunology: An overview, in Bystryn J-C, Ferrone S, Livingston P (eds): Specific immunotherapy of cancer with vaccine. Ann NY Acad Sci 1993; 690:24-33.
2. Osband M, Plummer J: Autolymphocyte therapy: Successful antigen-specific adoptive immunotherapy following non-specific activation. Clin Res 1989; 37:469A.
3. Carpinito G, et al: Successful adoptive immunotherapy of cancer using in vitro immunized autologous lymphocytes and cimetidine. Surg Forum 1986; XXVII:418.
4. Osband M: Successful adoptive immunotherapy of metastatic renal cell carcinoma with in vitro immunized autologous lymphocytes and cimetidine. World J Urol 1987; 4:217.
5. Osband M, et al: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990; 335:994-998.
6. Slavin S, et al.: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992; 10 (3): 221-227.
7. Zhoul M, Findleyl HW, Ragab AH: Low molecular weight B-cell growth factor and recombinant Interleukin-2 are together to regenerate cytotoxic T lymphocytes with LAK activity from the bone marrow cells of children with acute lymphoblastic leukemia. Blood 1989; 74 (4):1355-1359.
8. Rosenberg SA, Spies P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocyte. Science 1986; 233:1318-1321.
9. Guo Y, Wu M, Chen H, et al.: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1993; 263:518-520.
10. Grabbe S, Beissert S, Schwarz T, Granstein RD: Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy. Immunol Today 1995; 16:117-120.
11. Abbas AK, Lichtman AH, Pober JS: Cellular and Molecular Immunology, 2nd edn. Philadelphia, WB Saunders, 1994, p. 192.
12. Union Internationale Contre le Cancer (UICC): TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours, 2nd edn. Berlin, Heidelberg, Springer, 1992. Edicién Española, Springer, Ibèrica, Barcelona, 1994, pp. 3-357.
13. ECOG: Eastern Cooperative Oncology Group and American Joint Commission for cancer staging and end results reporting.
14. World Health Organization: Expert Committee on Biological Standarization. Geneva, WHO Technical Report 1985; No 725:28-36.
15. Margni RA: Métodos utilizados para la identificación de Antígenos y Anticuerpos y otras metodologii as de uso inmunológico, in Margni RA (ed.): Innmunológía e Inmunoquímica, 4th edn. Buenos Aires, Editorial Panamericana, 1989, Vol. 29, pp. 539-542.
16. Fossati A: Hibridomas y anticuerpos monoclonales, in Margni RA (ed.): Inmunológía e Inmunoquímica, 4th edn. Editorial Panamericana, Buenos Aires, 1989, Vol. 30, pp. 559-570.
17. Lord E, McAdam A, Felcher A, et al.: Transfection of TGF-β producing tumors with IL2 elicits tumor rejection, in Bystryn J-C, Ferrone S, Livingstone P (eds): Specific immunotherapy of cancer with vaccines. Ann NY Acad Sci 1993; 690:346-348.
18. Revel M, Katz A, Eisenbach A, Feldman M, Haran-Ghera N, Harroch S, Chebath J: Interleukin 6 effects on tumor models in mice and on cellular regulation of transcription factor IRF-1. IL6 Symposium. Ann NY Acad Sci 1994 (in press).
19. McAdam A, Pulaski B, Harkins S, Hutter E, Frelinjer J, Lord E.: Coexpression of IL2 and βIFN enhances tumor immunity, in Bystryn J-C, Ferrone S, Livingston P, Specific immunotherapy of cancer with vaccines. Ann NY Acad Sci 1993; 690:349-351.
20. In Stat, Instant Statistics. Graph Pad Software, Inc Version 2.0, 1990-1993.